<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920617</url>
  </required_header>
  <id_info>
    <org_study_id>P1605-SUR-D23</org_study_id>
    <secondary_id>KEYNOTE-C54</secondary_id>
    <nct_id>NCT04920617</nct_id>
  </id_info>
  <brief_title>DPX-Survivac, Alone or in Combination With Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac, Alone or in Combination With Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoVaccine Technologies, Inc. (IMV Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmunoVaccine Technologies, Inc. (IMV Inc.)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b, randomized, open label study to assess the safety and efficacy of&#xD;
      DPX-Survivac alone or in combination with pembrolizumab, with and without low-dose&#xD;
      cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2b, randomized, open label study to assess the safety and efficacy of&#xD;
      DPX-Survivac alone or in combination with pembrolizumab, with and without low-dose&#xD;
      cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.&#xD;
&#xD;
      The study will enroll up to 152 subjects. Eligible subjects will be randomized (1:1:1) to&#xD;
      receive:&#xD;
&#xD;
        -  Arm 1: DPX-Survivac, pembrolizumab and intermittent, low-dose CPA; or,&#xD;
&#xD;
        -  Arm 2: DPX-Survivac and pembrolizumab; or,&#xD;
&#xD;
        -  Arm 3: DPX-Survivac&#xD;
&#xD;
      All subjects will receive two 0.5 mL doses of DPX-Survivac 3 weeks apart on day 7 (D7) and&#xD;
      D28 followed by up to twelve 0.1 mL doses of DPX-Survivac, 8 weeks apart (Q8W).&#xD;
&#xD;
      Subject randomized to Arm 1 or 2 will receive pembrolizumab intravenously (IV) at a flat dose&#xD;
      of 200 mg starting at D7 and on day 1 of each 3-week cycle thereafter (i.e., D28, D49, D70&#xD;
      etc.) (Q3W).&#xD;
&#xD;
      For subjects randomized to Arm 1, intermittent oral CPA at a dose of 50 mg twice a day (BID)&#xD;
      is administered from D0 to D6 (7 days) followed by 7 days off. This 14-day cycle of &quot;7 days&#xD;
      on and 7 days off&quot; will be repeated until the end of study treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) in each of the study arms</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Centrally evaluated using Lugano (2014)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in each of the study arms</measure>
    <time_frame>Approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) in each of the study arms</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Centrally evaluated using Lugano (2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response in each of the study arms</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Centrally evaluated using Lugano (2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival in each of the study arms</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Centrally evaluated using Lugano (2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) in each of the study arms</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Centrally evaluated using Lugano (2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate in each of the study arms</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Centrally evaluated using Lugano (2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Patient Reported Outcomes using the FACT-Lym Assessment</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>The FACT-Lym is a validated questionnaire that consists of a 27-item general core questionnaire (i.e., Functional Assessment of Cancer Therapy - General [FACT-G]) and a 15-item disease-specific questionnaire (Lymphoma Subscale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Patient Reported Outcomes using the EQ-5D-5L Assessment</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>The EQ-5D-5L is a 5-item measure that can be used to describe and value current overall health consisting of 5 items assessing mobility, self care, usual activities, pain/discomfort, and anxiety/depression.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Objective Response Rate (ORR) based on PD-L1 expression</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Centrally evaluated using Lugano (2014) and central assessment of PD-L1 using validated 22C3 assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to next treatment (TTNT) in each of the study arms</measure>
    <time_frame>Approximately 48 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival (OS) in each of the study arms</measure>
    <time_frame>Approximately 48 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to second objective disease progression (PFS2) in each of the study arms</measure>
    <time_frame>Approximately 48 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cell mediated immune response</measure>
    <time_frame>Approximately 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in immune cell infiltration in tumor biopsies</measure>
    <time_frame>Approximately 24 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Relapsed Diffuse Large B-cell Lymphoma</condition>
  <condition>Refractory Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: DPX-Survivac, pembrolizumab, CPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two 0.5 mL doses of DPX-Survivac three weeks apart followed by up to twelve 0.1 mL doses eight weeks apart. Pembrolizumab will be administered on the first day of every three week cycle at a flat dose of 200 mg. CPA will be self-administered 50 mg BID for 7 days on and 7 days off starting on D0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: DPX-Survivac, pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two 0.5 mL doses of DPX-Survivac three weeks apart followed by up to twelve 0.1 mL doses eight weeks apart. Pembrolizumab will be administered on the first day of every three week cycle at a flat dose of 200 mg. Subjects randomized to Arm 2 will not receive CPA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: DPX-Survivac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two 0.5 mL doses of DPX-Survivac three weeks apart followed by up to twelve 0.1 mL doses eight weeks apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPX-Survivac</intervention_name>
    <description>SC injection on D7 and D28, then every 8 weeks</description>
    <arm_group_label>Arm 1: DPX-Survivac, pembrolizumab, CPA</arm_group_label>
    <arm_group_label>Arm 2: DPX-Survivac, pembrolizumab</arm_group_label>
    <arm_group_label>Arm 3: DPX-Survivac</arm_group_label>
    <other_name>maveropepimut-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion every 3 weeks</description>
    <arm_group_label>Arm 1: DPX-Survivac, pembrolizumab, CPA</arm_group_label>
    <arm_group_label>Arm 2: DPX-Survivac, pembrolizumab</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPA</intervention_name>
    <description>50 mg twice daily, week on then week off</description>
    <arm_group_label>Arm 1: DPX-Survivac, pembrolizumab, CPA</arm_group_label>
    <other_name>Intermittent, low-dose cyclophosphamide</other_name>
    <other_name>Procytox</other_name>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 18 years of age who are willing and able to provide written informed consent&#xD;
&#xD;
          -  Have an ECOG performance status of ≤ 1.&#xD;
&#xD;
          -  Pathologically confirmed diagnosis of DLBCL, as defined by the 2016 World Health&#xD;
             Organization classification including DLBCL NOS high-grade B-cell lymphoma with MYC&#xD;
             and BCL2 and/or BCL6 rearrangements, Epstein-barr virus (EBV) positive DLBCL, and T&#xD;
             cell rich B cell lymphoma (TCRBCL). Subjects with DLBCL transformed from indolent&#xD;
             lymphoma (except for Richter's transformation) are eligible.&#xD;
&#xD;
          -  Subjects must have progressive disease following at least two (2) lines of prior&#xD;
             systemic therapy; prior treatment must have included an anthracycline and rituximab&#xD;
             (or another CD20-targeted agent).&#xD;
&#xD;
          -  Subjects must have failed or be ineligible for ASCT or CAR-T&#xD;
&#xD;
          -  Have at least one bi-dimensionally measurable lesion per Lugano (2014)&#xD;
&#xD;
          -  Willing to provide pre-treatment and on-treatment tumor biopsy tissue.&#xD;
&#xD;
          -  Meet protocol-specified laboratory requirements&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Primary CNS lymphoma or active secondary CNS involvement and/or lymphomatous&#xD;
             meningitis&#xD;
&#xD;
          -  Primary refractory disease, defined as: documented persistent disease at the&#xD;
             completion of first-line therapy, or progressive disease within 3 months of completion&#xD;
             of treatment&#xD;
&#xD;
          -  Chemotherapy, immunotherapy, major surgery, or investigational agent treatment within&#xD;
             28 days of D0 or 5 half-lives, whichever is shorter&#xD;
&#xD;
          -  Radiotherapy within 14 days of day 0&#xD;
&#xD;
          -  Autologous stem cell transplant (ASCT) or chimeric antigen receptor T cell (CAR-T)&#xD;
             therapy within 100 days prior to D0&#xD;
&#xD;
          -  Diagnosis of immunodeficiency disorder or history of active autoimmune disease that&#xD;
             has required systemic treatment in the past 2 years&#xD;
&#xD;
          -  Uncontrolled significant active infections (controlled Hepatitis B, Hepatitis C, or&#xD;
             HIV may be eligible)&#xD;
&#xD;
          -  Prior history of malignancy other than eligible lymphoma sub-types, unless the subject&#xD;
             has been free of the disease for ≥ 2 years prior to the start of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lee, MD</last_name>
      <phone>714-698-0300</phone>
      <email>ericlee@compcancercare.com</email>
    </contact>
    <contact_backup>
      <last_name>Haresh Jhangiani, MD</last_name>
      <phone>714-698-0300</phone>
      <email>hjhangiani1@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Hematology and Oncology</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Archana Pathak</last_name>
      <phone>727-344-6569</phone>
      <phone_ext>1025</phone_ext>
      <email>apathak@comphemonc.com</email>
    </contact>
    <contact_backup>
      <last_name>Debbie Kisko</last_name>
      <phone>727-942-7070</phone>
      <phone_ext>8002</phone_ext>
      <email>dkisko@comphemonc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pratibha Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christus St. Vincent Regional Cancer Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Gallegos</last_name>
      <phone>505-913-8935</phone>
      <email>Christopher.gallegos@stvin.org</email>
    </contact>
    <investigator>
      <last_name>Olivier Rixe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toledo Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Sholl</last_name>
      <phone>419-383-4553</phone>
      <email>jill.sholl@utoledo.edu</email>
    </contact>
    <investigator>
      <last_name>Danae Hamouda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Lakes Health Care System</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bipinkumar Amin, MD</last_name>
      <phone>605-882-6800</phone>
      <email>bipin.amin@prairielakes.com</email>
    </contact>
    <contact_backup>
      <last_name>Darcy Raethz, RN, ONC</last_name>
      <phone>605-882-6800</phone>
      <email>darcy.raethz@prairielakes.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bipinkumar Amin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saskatchewan Cancer Agency</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanaa Youssef</last_name>
      <email>Hanaa.morcosyoussef@saskcancer.ca</email>
    </contact>
    <investigator>
      <last_name>Mark Bosch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>T cell activation</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>CAR-T ineligible</keyword>
  <keyword>ASCT ineligible</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

